/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Company has nominated a lead.
LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)
Liminal BioSciences (LMNL) Provides R&D Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The third annual Alternatives Watch Research Investor Compendium commissioned by Vidrio Financial, has been released and showcases a strong.